The risk of venous thrombosis, including cerebral vein thrombosis, among women with thrombophilia and oral contraceptive use: A meta-analysis

Clinical and Applied Thrombosis/Hemostasis

Volumn 17, Issue 6, 2011, Pages

  Dayan, N ^a   Holcroft, C A ^a   Tagalakis, V ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

deep venous thrombosis; pulmonary embolism; thrombophilia; thrombosis; venous thromboembolism

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ARTICLE; ATYPICAL SITE THROMBOSIS; CEREBRAL VEIN THROMBOSIS; DATA EXTRACTION; DEEP VEIN THROMBOSIS; ETHICS; HUMAN; META ANALYSIS; ORAL CONTRACEPTION; PREVALENCE; PRIORITY JOURNAL; THROMBOPHILIA; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; COHORT STUDIES; CONTRACEPTIVES, ORAL; FEMALE; HUMANS; INTRACRANIAL THROMBOSIS; PREVALENCE; RISK FACTORS; THROMBOPHILIA; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 84857205745     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029610391652     Document Type: Article

References (69)

1. United Nations, Department of Economic and Social Affairs, Population Division (2009). World Contraceptive Use 2009(POP/DB/CP/Rev2009). http://www.un.org/esa/population/publications/contraceptive2005/WCU2005.htm. Accessed February 8, 2010.
2. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C.. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing prostagen components. Lancet. 1995 ; 346 (8990). 1589-1593 (Pubitemid 26001840)
3. Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD.. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ. 1996 ; 312 (7023). 83-88
4. Bloemenkamp KWM, Rosendaal FR, Buller HR, et al. Risk of venous thrombosis with the use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med. 1999 ; 159: 65-70 (Pubitemid 29044121)
5. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP.. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet. 1995 ; 346 (8990). 1593-1596 (Pubitemid 26001841)
6. Vandenbroucke JP, Rosing J, Bloemenkamp KWM, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med. 2001 ; 344: 1527-1535 (Pubitemid 32429213)
7. Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci PM.. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol. 1999 ; 19 (3). 700-703 (Pubitemid 29135174)
8. Bloemenkamp KW, Helmerhorst FM, Rosendaal FR, et al. Venous thrombosis, oral contraceptives and high factor VIII levels. JTH. 1999 ; 82: 1024-1027 (Pubitemid 29419713)
9. Gadelha T, Andre C, Juca AA, Nucci M.. Pro-thrombin 20210A and oral contraceptive use as risk factors for cerebral vein thrombosis. Cerebrovasc Dis. 2005 ; 19 (1). 49-52 (Pubitemid 40082258)
10. Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2006 ; 107: 1453-1472
11. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR.. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994 ; 344 (8935). 1453-1457 (Pubitemid 24351698)
12. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Vandenbroucke JP.. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med. 2000 ; 160: 49-52 (Pubitemid 30040972)
13. Cohen J.. A coefficient for agreement for nominal scales. Educ Psychol Meas. 1960 ; 20: 37-46
14. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA. 2000 ; 283 (15). 2008-2012 (Pubitemid 30214957)
15. DerSimonian R, Laird N.. Meta-analysis in clinical trials. Control Clin Trial. 1986 ; 7 (3). 177-187
16. Deeks JJ Higgins JPT Altman DG editors. Chapter 9: analysing data and undertaking meta-analyses. In: HigginsJPTGreenS eds. Cochrane Handbook for Systematic Reviews of InterventionsVersion 5.0.1 (updated September 2008). The Cochrane Collaboration; 2008. www.cochrane-handbook.org. Accessed June 4, 2008.
17. Bax L, Yu LM, Ikeda N, Tsuruta H, Moons KGM.. Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. BMC Med Res Methodol. 2006 ; 6: 50
18. BaxLYuLMIkedaNTsurutaHMoonsKGM.MIX: comprehensive free software for meta-analysis of causal research data; 2008. Version 1.7. http://mix-for-meta- analysis.info. Accessed May 21, 2008.
19. College Station, TX: StataCorp ; 2005 :
20. Simioni P, Sanson B-J, Prandoni P, et al. Incidence of venous thromboembolism in families with inherited thrombophilia. JTH. 1999 ; 81 (2). 198-202 (Pubitemid 29078302)
21. Bombeli T, Basic A, Fehr J.. Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems. Am J Hematol. 2002 ; 70 (2). 126-132
22. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Koster T, Bertina RM, Vandenbroucke JP.. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives. Thromb Haemost. 1998 ; 80 (3). 382-387 (Pubitemid 28438729)
23. Samuelsson E, Staffan H.. Incidence of venous thromboembolism in young Swedish women and possibly preventable cases among combined oral contraceptive users. Acta Obstet Gynecol Scand. 2004 ; 83 (7). 674-681 (Pubitemid 38938758)
24. Margaglione M, Brancaccio V, Ciampa A, Papa ML, Grandone E, Di Minno G.. Inherited thrombophilic risk factors in a large cohort of individuals referred to Italian thrombophilia centers: distinct roles in different clinical settings. Haematologica. 2001 ; 86 (6). 634-639 (Pubitemid 32601108)
25. Abdollahi M, Cushman M, Rosendaal FR.. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost. 2003 ; 1 (10). 2186-2190
26. Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR.. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA. 2005 ; 293 (19). 2352-2361 (Pubitemid 40676757)
27. Salobir B, Sabovic M.. Interleukin-6 and antiphospholipid antibodies in women with contraceptive-related thromboembolic disease. Obstet Gynecol. 2004 ; 104 (3). 564-70 (Pubitemid 40458846)
28. Al-Shanqeeti A, van HVA, Berntorp E, Rosendaal FR, Broze Jr GJ.. Protein Z and protein Z-dependent protease inhbitor. Determinants of level and risk of venous thrombosis. Thromb Haemost. 2005 ; 93 (3). 411-413 (Pubitemid 40392526)
29. Boncoraglio G, Carriero MR, Chiapparini L, et al. Hyperhomocysteinemia and other thrombophilic risk factors in 26 patients with cerebral venous thrombosis. Eur J Neurol. 2004 ; 11 (6). 405-409 (Pubitemid 39272945)
30. Van Vlijmen EF, Brouwer JL, Veeger NJ, Eskes TK, de Graeff PA, van der Meer J.. Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects: results from a retrospective family cohort study. Arch Intern Med. 2007 ; 167 (3). 282-289
31. Appenzeller S, Zeller CB, Annichino-Bizzachi JM, et al. Cerebral venous thrombosis: influence of risk factors and imaging findings on prognosis. Clin Neurol Neurosurg. 2005 ; 107 (5). 371-378 (Pubitemid 40980380)
32. Buccino G, Scoditti U, Pini M, Tagliaferri AR, Manotti C, Mancia D.. Low-oestrogen oral contraceptives as a major risk factor or cerebral venous and sinus thrombosis: evidence from a clinical series. Ital J Neurol Sci. 1999 ; 20 (4). 231-235
33. Poulter NR, Meirik O, Chang CL, Farley TMM, Marmot MG.. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet. 1995 ; 346 (8990). 1575-1582 (Pubitemid 26001838)
34. Mohanty D, Shetty S, Ghosh K, Pawar A, Abraham P.. Hereditary thrombophilia as a cause of Budd-Chiari syndrome: a study from Western India. Hepatology. 2001 ; 34 (pt 4). 666-670 (Pubitemid 32927989)
35. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C.. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing prostagen components. Lancet. 1995 ; 346 (8990). 1589-1593 (Pubitemid 26001840)
36. Ehrenforth S, Nemes L, Mannhalter C, et al. Impact of environmental and hereditary risk factors on the clinical manifestation of thrombophilia in homozygous carriers of factor V:G1691A. J Thromb Haemost. 2004 ; 2 (3). 430-436 (Pubitemid 40185654)
37. Belicova M, Lukac B, Dvorsky J, Peter G, Mokán M, Kubisz P.. Thromboembolic disease and present oral contraception. Clin Appl Thromb Hemost. 2003 ; 9 (1). 45-51 (Pubitemid 36298213)
38. Legnani C, Cini M, Cosmi B, Mattarozzi S, Lo MG, Palareti G.. Oral contraceptive use in women with poor anticoagulant response to activated protein C but not carrying the factor V Leiden mutation increases the risk of venous thrombosis. Thromb Haemost. 2004 ; 91 (4). 712-718 (Pubitemid 38477451)
39. Pabinger I, Schneider B.. Thrombotic risk of women with hereditary antithrombin III-, protein c- and protein S-deficiency taking oral contraceptive medication. Thromb Haemost. 1994 ; 71 (5). 548-552 (Pubitemid 24132949)
40. Mira Y, Aznar J, Estelles A, Vayá A, Villa P, Ferrando F.. Congenital and acquired thrombotic risk factors in women using oral contraceptives: clinical aspects. Clin Appl Thromb Hemost. 2000 ; 6 (3). 162-168 (Pubitemid 30663124)
41. Bokarewa MI, Blomback M, Bremme K.. Phospholipid antibodies and resistance to activated protein C in women with thrombophilia. Blood Coagul Fibrinolysis. 1995 ; 6 (5). 417-422
42. Andersen BS, Olsen J.. Oral contraception and factor V Leiden mutation in relation to localization of deep vein thrombosis. Thromb Res. 1998 ; 90 (4). 191-194 (Pubitemid 28352672)
43. Hillier CEM, Collins PW, Bowen DJ, Bowley S, Wiles CM.. Inherited prothrombotic risk factors and cerebral venous thrombosis. QJM. 1998 ; 91 (10). 677-680 (Pubitemid 28479298)
44. Ray JG, Langman LJ, Vermeulen MJ, Evrovski J, Yeo EL, Cole DE.. Genetics University of Toronto Thrombophilia Study in women (GUTTSI): genetic and other risk factors for venous thromboembolism in women. Curr Control Trials Cardiovasc Med. 2001 ; 2 (3). 141-149 (Pubitemid 32600519)
45. Andersen BS, Olsen J, Nielsen GL, et al. Third generation oral contraceptives and heritable thrombophilia as risk factors of non-fatal venous thromboembolism. Thromb Haemost. 1998 ; 79 (1). 28-31 (Pubitemid 28037051)
46. Bennet L, Odeberg H.. Resistance to activated protein C, highly prevalent amongst users of oral contraceptives with venous thromboembolism. J Intern Med. 1998 ; 244 (1). 27-32 (Pubitemid 28322602)
47. Cosmi B, Legnani C, Bernardi F, Coccheri S, Palareti G.. Role of family history in identifying women with thrombophilia and higher risk of venous thromboembolism during oral contraception. Arch Intern Med. 2003 ; 163 (9). 1105-1109 (Pubitemid 36548941)
48. Bhattacharyya M, Kannan M, Chaudhry VP, Saxena R.. Venous thrombosis: prevalence of prothrombotic defects in north Indian population. Indian J Pathol Microbiol. 2003 ; 46 (4). 621-624 (Pubitemid 39186233)
49. Ludemann P, Nabavi DG, Junker R, et al. Factor V Leiden mutation is a risk factor for cerebral venous thrombosis: a case-control study of 55 patients. Stroke. 1998 ; 29 (12). 2507-2510 (Pubitemid 28543998)
50. Weih M, Vetter B, Ziemer S, et al. Increased rate of factor V Leiden mutation in patients with cerebral venous thrombosis. J Neurol. 1998 ; 245 (3). 149-152 (Pubitemid 28135057)
51. Martinelli I, Battaglioli T, Pedotti P, Cattaneo M, Mannucci PM.. Hyperhomocysteinemia in cerebral vein thrombosis. Blood. 2003 ; 102 (4). 1363-1366 (Pubitemid 36988044)
52. Rodrigues CA, Rocha LKA, Morelli VM, Franco RF, Lourenco DM.. Prothrombin G20210A mutation, and not factor V Leiden mutation, is a risk factor for cerebral venous thrombosis in Brazilian patients. J Thromb Haemost. 2004 ; 2 (7). 1211-1212 (Pubitemid 40186105)
53. Spannagl M, Heinemann LAJ, Schramm W.. Are factor V leiden carriers who use oral contraceptives at extreme risk for venous thromboembolism?. Eur J Contracept Reprod Health Care. 2000 ; 5 (2). 105-112 (Pubitemid 30470061)
54. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM.. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med. 1998 ; 338 (25). 1793-1797 (Pubitemid 28277959)
55. Vaya A, Mira Y, Mateo J, et al. Prothrombin G20210A mutation and oral contraceptive use increase upper-extremity deep vein thrombotic risk. Thromb Haemost. 2003 ; 89 (3). 452-457 (Pubitemid 36329234)
56. Legnani C, Cini M, Cosmi B, Poggi M, Boggian O, Palareti G.. Risk of deep vein thrombosis: interaction between oral contraceptives and high factor VIII levels. Haematologica. 2004 ; 89 (11). 1347-1351 (Pubitemid 39540572)
57. Santamaria A, Mateo J, Oliver A, et al. Risk of thrombosis associated with oral contraceptives of women from 97 families with inherited thrombophilia: high risk of thrombosis in carriers of the G20210A mutation of the prothrombin gene. Haematologica. 2001 ; 86 (9). 965-971 (Pubitemid 32937706)
58. Conard J, Plu-Bureau Bahi N, Horellou MH, Pelissier C, Thalabard JC.. Progestogen-only contraception in women at high risk of venous thromboembolism. Contraception. 2004 ; 70 (6). 437-441 (Pubitemid 39488199)
59. Martinelli I, Battaglioli T, Bucciarelli P, Passamonti SM, Mannuccio MP.. Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities. Circulation. 2004 ; 110 (5). 566-570 (Pubitemid 39031174)
60. Legnani C, Palareti G, Guazzaloca G, et al. Venous thromboembolism in young women: role of thrombophilic mutations and oral contraceptive use. Eur Heart J. 2002 ; 23 (12). 984-990 (Pubitemid 35203878)
61. De Bruijn SFT, Stam J, Koopman MMW, Vandenbroucke JP.. Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users who are carriers of hereditary prothrombotic conditions. BMJ. 1998 ; 316 (7131). 589-592 (Pubitemid 28120990)
62. Aznar J, Vaya A, Estelles A, et al. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and Factor V Leiden and their interaction with oral contraceptives. Haematologica. 2000 ; 85 (12). 1271-1276 (Pubitemid 32063697)
63. Reuner KH, Ruf A, Grau A, et al. Prothrombin gene G20210 (A transition is a risk factor for cerebral venous thrombosis. Stroke. 1998 ; 29 (9). 1765-1769 (Pubitemid 28399961)
64. Cantu C, Alonso E, Jara A, et al. Hyperhomocysteinemia, low folate and vitamin B12 concentrations, and methylene tetrahydrofolate reductase mutation in cerebral vein thrombosis. Stroke. 2004 ; 35 (8). 1790-1794 (Pubitemid 38971852)
65. Ventura P, Cobelli M, Marietta M, Panini R, Rosa MC, Salvioli G.. Hyperhomocysteinemia and other newly recognized inherited coagulation disorders (factor V Leiden and prothrombin gene mutation) in patients with idiopathic cerebral vein thrombosis. Cerebrovasc Dis. 2004 ; 17 (2-3). 153-159 (Pubitemid 38529191)
66. Wu O, Robertson L, Langhorne P, et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost. 2005 ; 94 (1). 17-25 (Pubitemid 40974700)
67. Dentali F, Crowther M, Ageno W.. Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis. Blood. 2006 ; 107 (7). 2766-2773
68. Emmerich J, Rosendaal FR, Cattaneo M, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism - pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost. 2001 ; 86 (3). 809-816 (Pubitemid 32834190)
69. Gomes MPV, Deitcher SR.. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy. Arch Intern Med. 2004 ; 164 (18). 1965-1976 (Pubitemid 39390552)